News | September 02, 2021
Granules India receive DRDO licence to manufacture and market 2-DG
The drug has been granted permission by DCGI for emergency use as an adjunct therapy for Covid-19
The drug has been granted permission by DCGI for emergency use as an adjunct therapy for Covid-19
Acetaminophen extended-release tablets 650 mg is bioequivalent of the reference listed drug Tylenol
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
The company posted net profit of Rs.111.44 crores for the period ended June 30, 2020.
ranules now has a total of 38 ANDA approvals from US FDA.
Granules now has a total of 37 ANDA approvals from US FDA (36 Final approvals and 1 tentative approvals).
This facility plays an important role in Granules’ global manufacturing and supply network
The inspection is now closed, and no regulatory action has been recommended
This product has only one approved generic and one authorized generic with an addressable market share of US$ 172 million
Tablets will be manufactured at Granules' US-based facility located in Chantilly, Virginia
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
